<a href="https://laohu8.com/S/ACOGD">Alpha Cognition Inc.</a> Announces NMPA Acceptance of ZUNVEYL NDA for Alzheimer's Treatment in China
Alpha Cognition Inc., a biopharmaceutical company specializing in therapies for neurodegenerative disorders, announced that their partner, China Medical System Holdings Limited $(CMS)$, has received acceptance for their New Drug Application (NDA) by the National Medical Products Administration of China (NMPA). This NDA pertains to ZUNVEYL® (Benzgalantamine), a treatment aimed at mild-to-moderate Alzheimer's dementia. This milestone signifies a critical step toward potentially introducing this innovative therapy to the Asian market. Alpha Cognition is set to benefit from CMS's regulatory and commercial expertise in China and will receive financial gains such as regulatory and sales milestones, and royalties upon ZUNVEYL's approval for marketing in China and other Asian territories.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729192664) on July 29, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。